Medtronic Announces CE Mark and European Launch of TYRX™ Absorbable Antibacterial Envelope

Medtronic, Inc. has received CE (Conformité Européenne) Mark for the TYRX™ Absorbable Antibacterial Envelope. This innovative mesh envelope covers an implantable cardiac device to help stabilize the device after implantation and reduce surgical-site infections. The efficacy of the previous generation, non-absorbable TYRX™ Antibacterial Envelope* has been shown in three published studies, with new six-month follow-up data from the CITADEL/CENTURION Study presented at Cardiostim 2014. Six months following implantation, patients who received a single- or dual-chamber implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) replacement device with a TYRX Antibacterial Envelope experienced lower infection rates than a historical cohort of patients who were implanted without the envelope. Specifically, infection occurred in 0.2 percent of patients who received the envelope during an ICD or CRT implant, compared to 1.9 percent of patients who did not receive the envelope (pAbout Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. * The TYRX Antibacterial Envelope was previously marketed as the AIGISRX® Antibacterial Envelope.